Detalhe da pesquisa
1.
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Br J Haematol
; 203(5): 781-791, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37697469
2.
PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.
Eur J Haematol
; 111(2): 191-200, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37157906
3.
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
Br J Haematol
; 196(1): 136-145, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496035
4.
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Br J Haematol
; 193(4): 779-791, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876423
5.
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.
Cancer
; 125(4): 618-625, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30423211
6.
Treatment of Progressive Multifocal Leukoencephalopathy with IL-2 and Mirtazapine.
J Clin Immunol
; 44(4): 97, 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587706
7.
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Haematologica
; 104(1): 93-101, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093398
8.
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Curr Treat Options Oncol
; 19(3): 15, 2018 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29520446
9.
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Lancet
; 388(10044): 576-85, 2016 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27291994
10.
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Biol Blood Marrow Transplant
; 22(7): 1197-1205, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27040394
11.
Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group.
Am J Hematol
; 96(6): E200-E203, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33719144
12.
Stopping second-generation TKIs in CML.
Blood
; 129(7): 805-806, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28209750
13.
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
Am J Hematol
; 92(10): E602-E604, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28670773
14.
Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.
Neural Regen Res
; 13(11): 1871-1874, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30233054
15.
Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
Curr Med Res Opin
; 34(8): 1419-1430, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29583054
16.
Secondary intestinal lymphangiectasia due to multiple myeloma.
Gastrointest Endosc
; 74(3): 718-20, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21092952
17.
Measurement of genomic instability in preleukemic P190BCR/ABL transgenic mice using inter-simple sequence repeat polymerase chain reaction.
Cancer Res
; 63(16): 4895-8, 2003 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12941812
18.
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Clin Lymphoma Myeloma Leuk
; 15(12): 715-27, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26433906
19.
Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
N Engl J Med
; 354(24): 2623-4, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16775249
20.
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Leuk Res
; 26(11): 1011-6, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12363470